We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




RNA Sequencing Assay Gains EU Certification for Solid Tumor Profiling

By LabMedica International staff writers
Posted on 27 Oct 2026

Genomic profiling of solid tumors supports clinical management by detecting gene rearrangements and specific splice variants. More...

Combining RNA and DNA testing can identify more clinically actionable gene fusions than DNA testing alone. To support these workflows, a newly certified assay provides an RNA sequencing option under European diagnostic regulation.

The Tempus xR assay from Tempus AI, Inc. (Chicago, IL, USA) has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. Designed for solid tumor tissue analysis, the assay supports cancer genomic profiling for clinical management. The certification also covers Tempus’ quality management system for next-generation sequencing devices used in this setting.

Within this profiling workflow, xR detects gene rearrangements and specific splice variants in solid tumor tissue using RNA sequencing as part of a next-generation sequencing approach. Evidence supporting the combination of RNA and DNA analysis comes from a published study cited for the assay, which showed that combined Tempus RNA and DNA testing increases detection of clinically actionable gene fusions compared with DNA testing alone.

The IVDR certification supports continued access to xR in the European Union beyond 2028. That year is the transition deadline for eligible legacy Class C devices. The certification also provides biopharma partners with an IVDR-certified testing platform to support clinical studies.

“Securing our European IVDR certification for xR reinforces our commitment to meeting the highest regulatory standards globally. This achievement establishes a strong regulatory foundation in Europe as we work to expand access to our advanced RNA sequencing tools for healthcare providers, biopharma partners and cancer patients across the region,” said Lauren Silvis, SVP of External Affairs at Tempus.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.